Revolution Medicines, Inc. (NASDAQ:RVMD)
| Market Cap | $34.87B+127.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a-94.6% |
| EPS | n/a-76.6% |
| Shares Out | 216.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,739,343 |
| Open | $161.61 |
| Previous Close | $159.43 |
| Day's Range | $160.24 - $169.51 |
| 52-Week Range | $69.50 - $224.31 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | $258.28(+60.22%) |
| Earnings Date | n/a |
About RVMD
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
13 firms rating RVMD in the last 3 months, one vote each. Issuer-paid research is not counted.
$RVMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RVMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RVMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RVMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RVMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RVMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RVMD
| VTIVanguard Morningstar Total Stock Market ETF | $977.25M |
| VBVanguard Morningstar Small-Cap ETF | $873.35M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $488.79M |
| VXFVanguard Extended Market ETF | $441.79M |
| IBBiShares Biotechnology ETF | $239.01M |
| IWPiShares Russell Mid-Cap Growth ETF | $171.93M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RVMD’s recent data — informational, not investment advice
What’s Behind the Score
News check: EU regulatory approval for lead pancreatic cancer drug, strong clinical data, and competitive positioning offset valuation concerns.
Recent Insider Activity
Insider Score Trend Over Time
-34.0 since Aug 26Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| CANC | Tema Oncology ETF | 5.34% |
| HLTH | Tema Healthcare AI ETF | 5.05% |
| BBH | VanEck Biotech ETF | 3.52% |
| ADPV | Adaptiv Select ETF | 3.47% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 3.39% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 3.38% |
| HRTS | Tema Heart & Health ETF | 3.16% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 3.06% |
| MEDI | Harbor Health Care ETF (MEDI) | 2.79% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 2.43% |
| DRKY | VistaShares Target 15 DRUKMacro Distribution ETF | 2.39% |
| IBB | iShares Biotechnology ETF | 2.35% |
Weight is the stock’s share of each fund’s holdings.
